Literature DB >> 7357552

Pharmacokinetic basis for differences in methotrexate sensitivity of normal proliferative tissues in the mouse.

F M Sirotnak, D M Moccio.   

Abstract

Following s.c. administration of varying doses of methotrexate (12 to 400 mg/kg) to mice, the drug accumulated more rapidly and to much higher levels in the small intestine in comparison to bone marrow. The persistence of exchangeable levels of drug (i.e. above that presumed to be equal to the dihydrofolate reductase-binding capacity) was also much greater in the small intestine. In addition, the more prolonged persistence of exchangeable drug in the small intestine compared to marrow correlated with a substantially longer duration of inhibition of DNA synthesis ([6-3H]deoxyuridine incorporation) in the former. Earlier recovery of DNA synthesis as a consequence of more rapid loss of drug appears to explain the lower sensitivity of marrow compared to small intestine to the effects of this agent in mice. These studies extend prior studies in our laboratory to the two major host proliferative populations in mice and allow us to propose that the property for accumulating and maintaining pharmacologically effective intracellular levels of folate analogs is differential among all proliferative tissues (tumor and normal) of this animal and probably in higher mammals as well.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357552

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Sleeping Beauty-Mediated Drug Resistance Gene Transfer in Human Hematopoietic Progenitor Cells.

Authors:  Kendra A Hyland; Erik R Olson; R Scott McIvor
Journal:  Hum Gene Ther       Date:  2015-09-18       Impact factor: 5.695

2.  Clonogenic response of cells of murine intestinal crypts to 12 cytotoxic drugs.

Authors:  J V Moore
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Non-Fas(CD95/APO1)-mediated apoptosis of activated T cells inhibits the development of atherosclerosis.

Authors:  Leticia Esparza; Joaquin De Haro; Silvia Bleda; Francisco Acin
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-05-22

4.  New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties.

Authors:  F M Sirotnak; J I DeGraw; D M Moccio; L L Samuels; L J Goutas
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Effects of high-dose methotrexate on rat alveolar and inflammatory macrophage populations.

Authors:  J M Zeller; C M Buys; P W Gudewicz
Journal:  Inflammation       Date:  1984-09       Impact factor: 4.092

6.  Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia.

Authors:  Xiao Li; Zhongguo Sui; Fanbo Jing; Wen Xu; Xiangpeng Li; Qie Guo; Shuhong Sun; Xiaolin Bi
Journal:  Cancer Manag Res       Date:  2019-07-05       Impact factor: 3.989

7.  Intravitreal methotrexate infusion for proliferative vitreoretinopathy.

Authors:  Ama Sadaka; Robert A Sisk; James M Osher; Okan Toygar; Melinda K Duncan; Christopher D Riemann
Journal:  Clin Ophthalmol       Date:  2016-09-19

8.  Albumin-Methotrexate Prodrug Analogues That Undergo Intracellular Reactivation Following Entrance into Cancerous Glioma Cells.

Authors:  Itzik Cooper; Michal Schnaider-Beeri; Mati Fridkin; Yoram Shechter
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.